FIELD: pharmaceutics; medicine.
SUBSTANCE: invention relates to the use of a composition for treating and/or preventing a disease or syndrome associated with a viral infection in a subject in need thereof, where viral infection causes acute inflammation, directly or indirectly inducing disease or syndrome, and where the viral infection is a coronavirus infection MERS-CoV, wherein the composition comprises a therapeutically effective amount of alpha-1-antitrypsin (AAT) protein.
EFFECT: inhibition of penetration of MERS-CoV into cells.
8 cl, 26 dwg, 11 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC MONOCLONAL ANTIBODY AGAINST SARS-COV-2 | 2022 |
|
RU2791749C1 |
| METHODS FOR TREATING INFECTIOUS DISEASES CAUSED BY CORONAVIRUS | 2021 |
|
RU2772701C1 |
| THERAPEUTIC AGENT AGAINST CORONAVIRUS INCLUDING AN ELAEOCARPUS SYLVESTRIS EXTRACT | 2021 |
|
RU2780346C1 |
| 5-[4-(1,3-BENZOTHIAZOL-2-YL)PHENYL]-10,15,20-TRIS(1-METHYLPYRIDINIUM-3-YL)PORPHYRIN TRIIOODIDE, SHOWING THE BINDING PROPERTY OF THE SARS-CoV-2 VIRUS SPIKE PROTEIN | 2021 |
|
RU2773397C1 |
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING POLYNUCLEOTIDES, AND USE THEREOF FOR PREVENTING OR TREATING COVID-19 | 2021 |
|
RU2824489C1 |
| METHOD FOR THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2775966C1 |
| RECOMBINANT RBD S-PROTEIN OF CORONAVIRUS SARS-CoV-2 AND METHOD FOR ITS PRODUCTION | 2023 |
|
RU2833839C1 |
| METHOD FOR CREATING RECOMBINANT ENTEROCOCCUS L3-SARSN1 STRAIN BASED ON BIOLOGICALLY ACTIVE ENTEROCOCCUS FAECIUM L3 STRAIN | 2022 |
|
RU2820058C1 |
| COMPOSITIONS AND METHODS FOR TREATING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) | 2004 |
|
RU2411042C2 |
